A Phase 4 interventional study of Riboflavin Ophthalmic Solutions and UV-A Irradiation System in Keratoconus, sponsored by Glaukos Corporation. Recruiting at 1 site in United States. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.
Sponsored by Glaukos Corporation · Phase 4, Interventional, and Treatment
Among 94 studies in Keratoconus with a site in United States — 27 open to participants now, 34 under way, 9 of them phase 3. Keratoconus · United States.
Among the 94 studies in Keratoconus with a site in United States, this one is the 56th largest by planned enrollment of the 71 interventional ones, is one of 5 that started in 2026, is one of 4 in phase 4, reaches primary completion later than 19 of the 33 other live ones, and was the 90th registered.
313 studies on the registry are indexed under Keratoconus; 56 are open to participants now.
This study's planned enrollment of 15 is below the median of 40 across 205 interventional studies indexed under Keratoconus.
Browse Keratoconus studies →27 of the 94 studies in Keratoconus with a site in United States are open now, in 12 countries. Each count lists the studies.
Of the 37 Keratoconus studies recruiting now, 21 (57%) set no upper age limit and 11 (30%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.
This study: 13 Years and older · all sexes · no healthy volunteers.
The full table on the hub →94 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 5 started in 2026.
Median enrollment 147 across the 71 interventional studies, 168 across the 21 observational. Of the 42 that completed or were terminated, 15 (36%) have results posted.
29 of 94 have an industry lead sponsor. The 10 most frequent:
Glaukos Corporation is the lead sponsor of 67 studies on the registry; 14 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 7 (54%) have results posted.
Glaukos Corporation has 9 studies filed under Keratoconus — fewer than ten, so there is no comparison to draw.
9 of the studies in Keratoconus with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07768735Alcon ResearchUNITY DX Cornea Study | 2026-11 |
| NCT06235567Maanasa Indaram, MDDextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking | 2026-12 |
| NCT03760432Oregon Health and Science UniversityCollagen Cross-linking in Keratoconus | 2026-12 |
| NCT07400952Glaukos CorporationPlacebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus | 2027-04 |
| NCT03030755The Cleveland ClinicCorneal Elastography and Patient Specific Modeling | 2027-05 |
Among the 94 studies in Keratoconus with a site in United States, from their registry updates:
Clinical trial to evaluate the safety and feasibility of corneal cross-linking in both eyes on the same day in subjects with keratoconus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Epioxa™ HD/Epioxa™ and UV-A Irradiation using the O2n™ System and Supplemental Oxygen using the Boost Goggles®
Drug: Riboflavin Ophthalmic Solutions · Device: UV-A Irradiation System
Riboflavin Ophthalmic Solutions
O2n UV-A Irradiation System
Successful completion of bilateral epithelium-on corneal collagen cross-linking.
Portion of subjects that the Investigator completed bilateral epithelium-on corneal collagen cross-linking treatment on the same day.
Time frame: Approximately 2.5 Months
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Sep 2027, 16 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.